Platelets in NSCLC patients also express PD-L1, which inhibits CD4 and CD8 T cells and contributes to tumor immune escape (115).Tumor cell-induced platelet aggregation (TCIPA) is another factor that impacts malignancy in CTC-platelet interactions. Here, CD8A is linked to neoplasm.